Autolus Therapeutics (AUTL) Cash from Operations (2017 - 2025)
Autolus Therapeutics' (AUTL) quarterly Cash from Operations came in at 67323000.0 in Q4 2025, down 77.47% YoY from 298868423.87 in Q4 2024, and up 0.85% on a QoQ basis from 67899000.0 in Q3 2025.
Autolus Therapeutics (AUTL) Cash from Operations (2017 - 2025) Analysis & Trends
Autolus Therapeutics (AUTL) has 9 years of Cash from Operations data on file, last reported at 67323000.0 in Q4 2025.
- Quarterly Cash from Operations fell 77.47% year-over-year to 67323000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 283568000.0 (down 37.47% YoY) and the FY2025 annual result came in at 283568000.0, down 37.47% from the prior year.
- Cash from Operations advanced to 67323000.0 in Q4 2025, from 67899000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 9158000.0 in Q4 2021 to a low of 76740000.0 in Q3 2024.
- A 5-year average of 43279750.0 and a median of 38040500.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2021 — Cash from Operations jumped 66.97% — and 2024, when it tumbled 90.95%.
- Tracing AUTL's Cash from Operations over 5 years: stood at 9158000.0 in 2021, then plunged by 59.05% to 14566000.0 in 2022, then tumbled by 70.49% to 24833000.0 in 2023, then plunged by 52.76% to 37934000.0 in 2024, then tumbled by 77.47% to 67323000.0 in 2025.
- The last three Cash from Operations figures came in at 67323000.0 (Q4 2025), 67899000.0 (Q3 2025), and 72781000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Autolus Therapeutics | 763.37 Mn | 561.74 Mn | 25.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -67.32 Mn |
| Dec 31, 2025 | -67.32 Mn |
| Sep 30, 2025 | -67.90 Mn |
| Sep 30, 2025 | -67.90 Mn |
| Jun 30, 2025 | -72.78 Mn |
| Jun 30, 2025 | -72.78 Mn |
| Mar 31, 2025 | -75.57 Mn |
| Mar 31, 2025 | -75.57 Mn |
| Dec 31, 2024 | -37.93 Mn |
| Dec 31, 2024 | -37.93 Mn |
| Sep 30, 2024 | -76.74 Mn |
| Sep 30, 2024 | -76.74 Mn |
| Jun 30, 2024 | -51.08 Mn |
| Jun 30, 2024 | -51.08 Mn |
| Mar 31, 2024 | -40.51 Mn |
| Mar 31, 2024 | -40.51 Mn |
| Dec 31, 2023 | -24.83 Mn |
| Dec 31, 2023 | -24.83 Mn |
| Sep 30, 2023 | -40.19 Mn |
| Sep 30, 2023 | -40.19 Mn |